GlassScriptPhysician profile
Avnish Clerk
NPI 1316105828
$89,082.48
in general payments reported to CMS, 2019-2025
28 companies · $8,524 in 2025
The $8,524 reported for 2025 was more than what 86% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $4,357 · 2021: $31K · 2022: $19K · 2023: $3,551 · 2024: $21K · 2025: $8,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $11K · Food and Beverage: $5,704 · Gift: $23.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,200.00 |
| Travel and Lodging | $10,940.50 |
| Food and Beverage | $5,704.34 |
| Gift | $23.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $59,828.07 | 2019-2025 | Flexible Guide Pin (Stryker Acl Versitomic), Alphavent, Blueprint Patient Specific Instrumentation |
| Shoulder Innovations, INC. | $7,045.70 | 2022-2025 | Inset System |
| Depuy Synthes Products, INC. | $6,412.50 | 2020-2021 | |
| Medical Device Business Services, INC. | $5,935.53 | 2020-2022 | |
| Lima USA, INC. | $2,105.39 | 2022-2023 | Smr Shoulder |
| Depuy Synthes Sales INC. | $1,127.60 | 2020-2025 | Na, Dynacord, Dynatape |
| Zimmer Biomet Holdings, INC. | $750.38 | 2019-2025 | Comprehensive Shoulder System, Tapestry, Oxford |
| Pacira Pharmaceuticals Incorporated | $709.37 | 2019-2025 | Exparel, Iovera |
| Powerlink Ai, INC. | $663.01 | 2025 | |
| Medacta USA, INC. | $605.04 | 2023 | Amistem, Mecta |
| Ethicon US, LLC | $555.22 | 2022-2025 | Ethicon, Vistaseal, Stratafix |
| Linvatec Corporation | $427.46 | 2019 | |
| Trice Medical, INC. | $367.64 | 2019 | |
| Pacira Therapeutics, INC. | $355.35 | 2019-2021 | |
| Arthrex, INC. | $338.31 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $325.03 | 2022-2023 | Durolane |
| Smith+Nephew, INC. | $278.88 | 2022-2023 | Evos, Trigen Intertan |
| Catalyst Orthoscience | $257.15 | 2020 | |
| Innovation Technologies INC | $147.22 | 2024 | Irrisept |
| Djo, LLC | $146.51 | 2019 | |
| Acumed LLC | $120.69 | 2021 | |
| Kairos Surgical INC | $119.96 | 2023 | |
| Lifenet Health | $119.64 | 2025 | Pliafx Flo |
| Miach Orthopaedics, INC. | $119.00 | 2023 | |
| Skeletal Dynamics INC | $106.56 | 2025 | Align, Implate, Ijs |
| Vertex Pharmaceuticals Incorporated | $56.90 | 2025 | |
| Avanos Medical | $50.12 | 2022 | |
| Biedermann Motech, INC. | $8.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,199.36 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avnish Clerk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.